Benoit You, MD, PhD, Centre Hospitalier Lyon-Sud, Saint-Genis-Laval, France, talks on areas of unmet need in ovarian cancer. Patients with ovarian cancer suffer from poor prognosis, calling for improved and innovative treatment strategies. Bevacizumab and PARP inhibitors have been introduced into the treatment landscape for this patient population, but which agent patients should be treated with or whether a combination is required remains uncertain. HR status, genomic instability status and whether a patient is chemosensitive can aid in treatment decision making, however, Dr You emphasizes further improvements are needed. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.